Drugs / NG-641
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05043714 | Dec 2021 → Nov 2023 | epithelial neoplasm, metastatic malignant neoplasm | Akamis Bio | Completed | No outcome recorded |
| Phase 1 | NCT04830592 | Nov 2021 → Dec 2023 | head and neck squamous cell carcinoma | Akamis Bio | Completed | No outcome recorded |
| Phase 1 | NCT04053283 | Jan 2020 → Aug 2023 | epithelial neoplasm, metastatic malignant neoplasm | Akamis Bio | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01176552 | May 2004 → Sep 2008 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00420888 | Jan 2007 → Jan 2013 | renal cell carcinoma | Active Biotech AB | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-03-07 | Bristol-Myers Squibb | Results New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗
Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV Genotype 1 null responders (Late-Breakers Oral Session) |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-03-07 | Bristol-Myers Squibb | New Data on Multiple Bristol-Myers Squibb Investigational Hepatitis C Compounds to be Presented at The International Liver Congress 2011 bms.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG-641 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04053283 ↗ |
| Known as | IFN | “granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon alpha (IFN) and interleukin-2 (IL-2)” NCT01176552 ↗ |
| Known as | IFN alpha | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01176552 ↗ |
| Known as | interferon alpha | “granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon alpha (IFN) and interleukin-2 (IL-2)” NCT01176552 ↗ |
| Action | Deplete | “This can lead to killing of tumor cells” NCT04830592 ↗ |
| Route | Intramuscular | “3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week” NCT00420888 ↗ |
| Route | Subcutaneous | “3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week” NCT00420888 ↗ |
| Target | FAP | “targeting fibroblast activation protein (FAP)” NCT04053283 ↗ |